FMP

FMP

Datasets
Market NewsEducationHow ToDiscounted Cash Flow ModelDeveloper

Walgreens Boots Alliance Reports Q2 Beat, But Guidance Implies Significant Deceleration in H2/22

Walgreens Boots (NASDAQ:WBA) shares lost around 7% since the company’s reported Q2 results two days ago. While the company beat the Street expectations, the guidance of low-single-digit EPS growth was reiterated, implying a significant deceleration in H2/22 due to labor and Walgreens Health investments.

Q2 adjusted EPS came in at $1.59, compared to the estimates of $1.37, and revenue at $33.76 billion, compared to the consensus of $33.32 billion. The company benefited from strong vaccination and testing demand, solid US retail demand, and continued improvement in international markets.

Analysts at RBC Capital reiterated their Sector Perform rating but lowered their price target to $46 from $52 as they roll their valuation forward to 2023 to reflect a more normalized post-pandemic operating backdrop.